Important Notice regarding Dextenza and Klarity-C

Posted in Latest News on October 15, 2019.

During the September 27, 2019 Board of Optometry meeting, the Board approved Dextenza (dexamethasone ophthalmic insert) 0.4 mg and approved Klarity-C (cyclosporine) 0.1% for addition to Rule 64B13-18.002, Florida Administrative Code – Formulary of Topical Pharmaceutical Agents.

Important Note: At this time, Dextenza and Klarity-C cannot be prescribed by Certified Optometrists in Florida until the rule has been approved. Once the rule has gone through the approval process, notice will be provided on the board website and both may be prescribed by Certified Optometrists at that time.



More Latest News

NTSB Study on Drug Use Trends in Aviation
March 8, 2021

National Transportation Safety Board issues recommendations to states on prescribing controlled substances for pain and the dangers of operating a vehicle in any mode of transportation Continue reading


Second Quarter Performance Report
March 4, 2021

Released for Fiscal Year
2020-2021 Continue reading